Richard Joseph Pietras

List of Publications by Year
in descending order

81	6,937	71061	79644
papers	citations	41 h-index	73 g-index

87	87	87	5067
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature, 1977, 265, 69-72.	13.7	663
2	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 1999, 18, 2241-2251.	2.6	645
3	Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 739-749.	3.0	488
4	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17, 2235-2249.	2.6	353
5	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 1997, 15, 537-547.	2.6	317
6	Endometrial cell calcium and oestrogen action. Nature, 1975, 253, 357-359.	13.7	247
7	Usefulness of 3â€²-[F-18]Fluoro-3â€²-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy. Molecular Imaging and Biology, 2006, 8, 36-42.	1.3	208
8	Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids, 2007, 72, 135-143.	0.8	198
9	Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids, 2005, 70, 372-381.	0.8	180
10	Estrogen receptors in uterine plasma membrane. The Journal of Steroid Biochemistry, 1979, 11, 1471-1483.	1.3	172
11	Aromatase Inhibitors in Human Lung Cancer Therapy. Cancer Research, 2005, 65, 11287-11291.	0.4	161
12	Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene, 2001, 20, 5420-5430.	2.6	158
13	Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Research and Treatment, 2008, 108, 351-361.	1.1	150
14	Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochemical Journal, 1980, 191, 743-760.	1.7	145
15	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 1999, 18, 6050-6062.	2.6	131
16	Aromatase Expression Predicts Survival in Women with Early-Stage Nonâ€“Small Cell Lung Cancer. Cancer Research, 2007, 67, 10484-10490.	0.4	126
17	Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clinical Cancer Research, 2007, 13, 4672-4676.	3.2	123
18	Routes of nonelectrolyte permeation across epithelial membranes. Journal of Membrane Biology, 1974, 17, 293-312.	1.0	114

#	Article	IF	Citations
19	Targeting Aromatase and Estrogen Signaling in Human Nonâ€Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 194-205.	1.8	106
20	The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis, 2006, 27, 2424-2433.	1.3	94
21	Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: Regulation of estrogen-dependent gene transcription. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2632-2636.	3.3	93
22	Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Molecular and Cellular Endocrinology, 2006, 246, 91-100.	1.6	92
23	Rational management of endocrine resistance in breast cancer. Cancer, 2008, 113, 2385-2397.	2.0	79
24	Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene, 2002, 21, 2805-2814.	2.6	76
25	Interactions Between Estrogen and Growth Factor Receptors in Human Breast Cancers and the Tumor-Associated Vasculature. Breast Journal, 2003, 9, 361-373.	0.4	73
26	Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding-sites specific for estradiol-17?. Journal of Cellular Physiology, 1979, 98, 145-159.	2.0	70
27	Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Research and Treatment, 2005, 93, 11-18.	1.1	70
28	Lysosomal Functions in Cellular Activation: Propagation of the Actions of Hormones and Other Effectors. International Review of Cytology, 1984, 88, 1-302.	6.2	69
29	Membrane receptors for steroid hormones: Signal transduction and physiological significance. Journal of Cellular Biochemistry, 2003, 88, 438-445.	1.2	69
30	Steroid Hormone Receptors in Target Cell Membranes. Endocrine, 2001, 14, 417-428.	2.2	68
31	Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids, 2011, 76, 910-20.	0.8	65
32	Epidermal Growth Factor Receptor and Tyrosine Phosphorylation of Estrogen Receptor. Endocrine, 2001, 16, 073-082.	2.2	62
33	Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer, 2011, 74, 318-325.	0.9	62
34	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 270-278.	0.5	59
35	Targeted Therapy: Wave of the Future. Journal of Clinical Oncology, 2005, 23, 1776-1781.	0.8	57
36	Electrically and osmotically induced changes in permeability and structure of toad urinary bladder. Biochimica Et Biophysica Acta - Biomembranes, 1974, 332, 286-297.	1.4	56

#	Article	IF	Citations
37	Membrane Recognition and Effector Sites in Steroid Hormone Action. , 1981, , 307-463.		56
38	The membrane action of antidiuretic hormone (ADH) on toad urinary bladder. Journal of Membrane Biology, 1975, 22, 107-123.	1.0	51
39	Elevated serum cathepsin B1-like activity in women with neoplastic disease. Gynecologic Oncology, 1979, 7, 1-17.	0.6	51
40	Antiangiogenic Steroids in Human Cancer Therapy. Evidence-based Complementary and Alternative Medicine, 2005, 2, 49-57.	0.5	48
41	Estrogen Receptors and Cell Signaling. Science, 2005, 310, 51-53.	6.0	47
42	Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105415.	1.2	44
43	Biologic Basis of Sequential and Combination Therapies for Hormoneâ€Responsive Breast Cancer. Oncologist, 2006, 11, 704-717.	1.9	43
44	Surface Modifications Evoked by Estradiol and Diethylstilbestrol in Isolated Endometrial Cells: Evidence from Lectin Probes and Extracellular Release of Lysosomal Protease. Endocrinology, 1975, 97, 1445-1454.	1.4	40
45	Steroid Hormone-Responsive, Isolated Endometrial Cells. Endocrinology, 1975, 96, 946-954.	1.4	39
46	A83-01 inhibits TGF-Î²-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Research and Treatment, 2017, 163, 449-460.	1.1	39
47	Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget, 2018, 9, 33912-33930.	0.8	39
48	Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Molecular and Cellular Endocrinology, 2018, 466, 51-72.	1.6	38
49	Non-electrolyte Probes of Membrane Structure in ADH-treated Toad Urinary Bladder. Nature, 1974, 247, 222-224.	13.7	37
50	Biologic Roles of Estrogen Receptor-Î²and Insulin-Like Growth Factor-2 in Triple-Negative Breast Cancer. BioMed Research International, 2015, 2015, 1-15.	0.9	35
51	CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget, 2017, 8, 38294-38308.	0.8	35
52	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	0.9	35
53	New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resistance Updates, 2005, 8, 219-233.	6.5	34
54	Specific internalization of estrogen and binding to nuclear matrix in isolated uterine cells. Biochemical and Biophysical Research Communications, 1984, 123, 84-91.	1.0	32

#	Article	IF	Citations
55	Influence of antidiuretic hormone on release of lysosomal hydrolase at mucosal surface of epithelial cells from urinary bladder. Nature, 1975, 257, 493-495.	13.7	29
56	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Management, 2012, 1, 259-272.	1.5	27
57	Ribonucleotide Reductase Subunit M2 Predicts Survival in Subgroups of Patients with Non-Small Cell Lung Carcinoma: Effects of Gender and Smoking Status. PLoS ONE, 2015, 10, e0127600.	1.1	27
58	Cell membrane estrogen receptors resurface. Nature Medicine, 1999, 5, 1330-1330.	15.2	26
59	Subcellular distribution of oestrogen receptors. Nature, 1985, 317, 88-88.	13.7	24
60	Differential effects of vasopressin on the water, calcium and lysosomal enzyme contents of mitochondria-rich and lysosome-rich (granular) epithelial cells isolated from bullfrog urinary bladder. Molecular and Cellular Endocrinology, 1976, 4, 89-106.	1.6	22
61	Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Cancer Letters, 2016, 374, 279-291.	3.2	22
62	Sex pheromone production by preputial gland: the regulatory role of estrogen. Chemical Senses, 1981, 6, 391-408.	1.1	20
63	Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Letters, 2019, 449, 66-75.	3.2	17
64	Vasopressin-induced redistribution of binding sites for concanavalin A at the surface of epithelial cells from urinary bladder. Nature, 1976, 264, 774-776.	13.7	16
65	Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 2305.	1.8	14
66	Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. Journal of Medical Case Reports, 2016, 10, 346.	0.4	12
67	Estrogen Receptor-Î² and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Critical Reviews in Oncogenesis, 2015, 20, 373-390.	0.2	6
68	Surface modifications evoked by antidiuretic hormone in isolated epithelial cells: Evidence from lectin probes. Journal of Supramolecular Structure, 1975, 3, 391-400.	2.3	5
69	Immunologic inhibition of estrogen binding and action in preputial-gland cells and their subcellular fractions. The Journal of Steroid Biochemistry, 1981, 14, 679-691.	1.3	5
70	Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. Case Reports in Cardiology, 2017, 2017, 1-6.	0.1	5
71	Progesterone Receptor Signaling in the Breast Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1329, 443-474.	0.8	4
72	Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models. Translational Lung Cancer Research, 2018, 7, S373-S376.	1.3	2

#	Article	IF	Citations
73	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. JTO Clinical and Research Reports, 2021, 2, 100150.	0.6	2
74	Plasma Membrane Receptors for Steroid Hormones in Cell Signaling and Nuclear Function. , 2005, , 67-84.		2
75	Membrane-Associated Estrogen Receptors and Breast Cancer. , 2003, , 1-9.		2
76	Membrane Steroid Receptors. , 2003, , 657-671.		1
77	Oncogene Activation and Breast Cancer Progression. , 1999, , 133-153.		1
78	Membrane Steroid Receptors â˜†. , 2017, , .		1
79	In Memorium: Clara M. Szego (1916â€“2017). Steroids, 2018, 135, 98-100.	0.8	0
80	Estrogen-Induced Growth of Uterine Cells. , 1981, , 649-674.		0
81	SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. Journal of the Endocrine Society, 2020, 4, .	0.1	0